<DOC>
	<DOCNO>NCT00192231</DOCNO>
	<brief_summary>The primary objective study perform variety immunological assay blood , serum , nasal wash sample , cell obtain healthy adult subject purpose develop assay application investigation immune response generate influenza virus vaccine , trivalent , type A B , live , cold-adapted ( liquid CAIV-T ) .</brief_summary>
	<brief_title>Trial Investigate Immune Responses Elicited Liquid Formulation Influenza Virus Vaccine , ( CAIV-T )</brief_title>
	<detailed_description />
	<mesh_term>Influenza , Human</mesh_term>
	<criteria>Healthy adult age 18 59 year &gt; 60 year . Female subject childbearing potential negative urine pregnancy test result prior study vaccination . Females surgically sterilize postmenopausal require pregnancy test . Adults determine medical history , physical examination clinical judgment eligible study . Subjects stable preexist disease , define disease require change therapy hospitalization within 12 week receipt study vaccination , eligible . Subjects provide write informed consent nature study explain . Subjects available duration study ( enrollment study completion ) . Subjects could reach study staff postvaccination contact [ via telephone , clinic home visit ] . Subjects reside nursing home longterm care facility institution receive skilled semiskilled nursing care . An ambulatory subject reside retirement home village eligible participation . Subjects evidence dementia severe cognitive impairment base Mini Mental State Examination ( MMSE ) score 22 great . Note : Administration MMSE perform clinically indicate . For study subject : Subjects perceive unavailable difficult contact evaluation study visit study period . Subjects know suspected disease immune system receive immunosuppressive therapy , include systemic corticosteroid ; cytotoxic agent . Subjects receive blood product , include immunoglobulin , period six month prior vaccination conclusion study . Subjects reside household immunosuppressed immunocompromised individual . Subjects document history hypersensitivity egg egg protein component study vaccine placebo . Subjects administer live virus vaccine within one month prior enrollment . Subjects intent administer investigational vaccine agent one month prior enrollment conclusion study . Subjects receive dose influenza treatment ( commercial investigational ) one month prior enrollment . Prophylactic use influenza antiviral permit . Subjects receive influenza vaccine six month prior enrollment , nonstudy influenza vaccine since enrollment . Subjects medical condition opinion investigator might interfere interpretation study result .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2006</verification_date>
</DOC>